GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Colan Totte Co 7792.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

1,441

+2.13%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥6.92bn

FY2019FY2025

Net income

¥1.33bn

FY2019FY2025

Free cash flow

¥728.7m

FY2019FY2025

Shareholders' equity

¥5.17bn

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue¥6.92bn¥5.94bn¥5.41bn¥4.66bn¥3.71bn¥2.89bn¥2.93bn
Gross profit¥4.66bn¥3.97bn¥3.45bn¥3.04bn¥2.46bn¥1.82bn¥1.76bn
Research and development—¥21.0m¥27.1m¥30.8m¥24.9m¥8.8m—
Operating income¥1.81bn¥1.50bn¥1.02bn¥951.3m¥646.4m¥504.5m¥453.7m
Net income¥1.33bn¥1.02bn¥645.0m¥610.5m¥420.5m¥324.8m¥271.3m
Diluted earnings per share145.52112.3270.7166.8346.0835.6029.74

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets¥6.74bn¥5.43bn¥4.91bn¥4.13bn¥3.62bn¥2.32bn¥2.22bn
Cash and short-term investments¥2.18bn¥1.76bn¥1.79bn¥1.34bn¥1.55bn¥507.3m¥434.4m
Total liabilities¥1.57bn¥1.32bn¥1.64bn¥1.38bn¥1.38bn¥1.44bn¥1.66bn
Debt¥12.9m¥8.7m¥1.3m¥270.5m¥439.8m¥912.1m¥1.14bn
Shareholders' equity¥5.17bn¥4.11bn¥3.27bn¥2.75bn¥2.24bn¥886.0m¥561.2m
Shares outstanding9m9m9m9m9m9m9m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations¥998.3m¥883.8m¥955.7m¥148.1m¥637.3m¥378.8m¥115.7m
Capital spending−¥269.6m−¥526.5m−¥88.4m−¥72.6m−¥39.9m−¥61.1m−¥49.6m
Free cash flow¥728.7m¥357.3m¥867.3m¥75.5m¥597.4m¥317.7m¥66.1m
Dividends paid−¥271.6m−¥180.3m−¥143.1m−¥106.8m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥2.53bn¥1.82bn¥2.51bn¥1.85bn¥1.84bn¥1.33bn¥1.90bn¥1.45bn
Gross profit¥1.78bn¥1.28bn¥1.69bn¥1.25bn¥1.23bn¥912.9m¥1.25bn¥980.6m
Operating income¥601.4m¥503.3m¥614.2m¥353.1m¥511.6m¥322.0m¥623.0m¥281.0m
Net income¥402.9m¥343.1m¥425.5m¥241.9m¥342.5m¥218.6m¥525.0m¥165.0m
Diluted earnings per share44.1537.6046.6226.5037.5223.9557.5618.09
Cash from operations—¥242.0m¥243.0m¥998.0m————
Capital spending—−¥79.0m−¥79.0m−¥269.0m————
Free cash flow—¥163.0m¥164.0m¥729.0m————
Total assets¥7.42bn¥7.18bn¥7.01bn¥6.74bn¥6.27bn¥6.00bn¥5.59bn¥5.43bn
Cash and short-term investments¥1.93bn¥2.11bn¥1.78bn¥2.18bn¥1.82bn¥2.00bn¥1.50bn¥1.76bn
Debt———¥3.2m———¥2.4m
Shareholders' equity¥5.96bn¥5.55bn¥5.21bn¥5.17bn¥4.92bn¥4.58bn¥4.36bn¥4.11bn

Financial ratios

Data as of 2 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin67.3%66.7%63.9%65.3%66.2%63.0%—
Operating margin26.2%25.2%18.8%20.4%17.4%17.5%—
Net margin19.2%17.2%11.9%13.1%11.3%11.2%—
Return on equity25.7%24.9%19.7%22.2%18.8%36.7%—
Return on assets19.7%18.9%13.1%14.8%11.6%14.0%—
Free cash flow yield7.4%6.5%7.0%1.1%———
Revenue growth16.4%10.0%15.9%25.5%28.7%-1.3%—
Earnings growth29.7%58.8%5.7%45.2%29.5%19.7%—
Current ratio3.16x2.97x2.47x2.71x2.51x1.49x—
Debt to equity0.00x0.00x0.00x0.10x0.19x1.02x—
Equity ratio76.7%75.7%66.6%66.5%61.9%38.1%—
Interest coverage——1413.66x673.71x221.29x41.98x30.29x
R&D as a share of sales—0.4%0.5%0.7%0.7%0.3%—
Buybacks as a share of market value-0.1%0.0%0.1%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue14.0%19.1%—
Operating income23.9%29.1%—
Net income29.6%32.5%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin67.1%65.9%65.7%—
Operating margin25.7%23.0%21.8%—
Net margin18.3%15.7%14.7%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings10.19.211.312.615.2
Price to sales1.91.61.41.61.7

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 29 Sept 2025.

FY2026FY2025FY2024FY2023FY2022
Paid in the year42.0030.0020.0016.0012.00

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.